Itolizumab + EQ001 Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Graft Versus Host Disease
Conditions
Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
Trial Timeline
Apr 29, 2022 → May 12, 2025
NCT ID
NCT05263999About Itolizumab + EQ001 Placebo
Itolizumab + EQ001 Placebo is a phase 3 stage product being developed by Biocon for Graft Versus Host Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05263999. Target conditions include Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05263999 | Phase 3 | Terminated |
Competing Products
20 competing products in Graft Versus Host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Prograf + Methotrexate + Cyclosporine | Astellas Pharma | Approved | 85 |
| Alefacept | Astellas Pharma | Phase 2 | 52 |
| tacrolimus | Astellas Pharma | Approved | 85 |
| Tacrolimus + Tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| EQ001 + EQ001 Placebo | Biocon | Phase 1/2 | 41 |
| SHR0302 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Acalabrutinib | AstraZeneca | Phase 2 | 52 |
| Aspirin + Ticagrelor | AstraZeneca | Approved | 85 |
| Sugammadex | Merck | Approved | 85 |
| Efprezimod alfa + Methotrexate + Tacrolimus + Placebo | Merck | Phase 2 | 52 |
| Ruxolitinib | Novartis | Approved | 85 |
| Imatinib Mesylate and Nilotinib | Novartis | Phase 2 | 52 |
| Prednisone + Jakavi(ruxolitinib) + Prednisone | Novartis | Phase 2 | 52 |
| PredEver | Novartis | Phase 2 | 52 |
| Lifitegrast 5% Ophthalmic Solution + Placebo | Novartis | Phase 1 | 33 |
| Cyclosporine | Novartis | Approved | 85 |
| Everolimus + Tacrolimus + Mycophenolic acid | Novartis | Approved | 85 |
| 1 + 2 | Novartis | Approved | 85 |
| Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte Globulin | Novartis | Approved | 85 |
Other Products from Biocon
Stelara + Bmab1200Phase 3
77
EQ001 + EQ001 PlaceboPhase 3
77
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringePhase 3
77
Bmab 1000 + Prolia®Phase 3
77
PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelPhase 3
77